Chronic Granulomatous Disease Market Latest Innovations, Drivers And Market Status 2022 To 2028
Chronic
Granulomatous Disease Market
Market Highlights
Chronic granulomatous disease (CGD) is a rare inherited
immune deficiency caused due to a random mutation in the DNA. People affected
with this disease have weakened immune systems which do not function properly.
CGD is of two types, namely, X-linked CGD and autosomal recessive type.
According to The Chronic Granulomatous Disorder Society, about 60% of people
with CGD have X-linked CGD. People with CGD generally have bacterial infections
including Salmonella, Klebsiella, Actinomyces, Streptococcus, Nocardia, and
Serratia among others. Moreover, fungal infections such as Aspergillus
fumigatus and Aspergillus nidulans are also common. The rising prevalence of
rare diseases, growing expenditure on healthcare sector in the developed
economies, and increasing research and development activities are expected to
drive the growth of the market over the forecast period. On the other hand, the
expensive diagnostic tests and treatment coupled with lack of awareness about
the disease in the developing and underdeveloped economies may hamper the
market growth over the assessment period.
The global Chronic
Granulomatous Disease Market is currently dominated by many market
players. The prominent players in the market are engaged in frequent new
product launches and strategic collaborations to strengthen its market
position. Currently, Actimmune (Interferon gamma-1b) manufactured by InterMune,
Inc. is the approved by the US Food and Drug Administration (FDA) for treatment
of chronic granulomatous disease.
Regional Analysis
The market in the Americas is expected to dominate the
global chronic granulomatous disease market during the forecast period owing to
the growing prevalence of rare diseases, increasing research and development,
and presence of well-developed healthcare sector. Europe is anticipated to hold
the second largest position in the global chronic granulomatous disease market.
The market growth in this region is attributed to the rising prevalence of rare
diseases and increasing research and development activities. Asia-Pacific is
expected to be the fastest growing market owing to the developing healthcare
infrastructure, increasing awareness about rare genetic diseases, and
increasing government funding for the healthcare sector. Furthermore, the
Middle East and Africa region is expected to hold the least share in the global
market owing to the slowly developing healthcare sector especially in the
African region.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/6447
Segmentation
The global chronic granulomatous disease market has been
segmented into type, diagnosis, treatment, and end user.
The market, on the basis of type, is segmented into X-linked
chronic granulomatous disease and autosomal recessive chronic granulomatous
disease.
The market, by diagnosis, has been segmented into neutrophil
function tests, genetic testing, prenatal testing, and others.
The market, by treatment, has been segmented into infection
management, interferon-gamma, stem cell transplantation, and others. The
infection management segment has been further segmented into trimethoprim,
sulfamethoxazole, itraconazole, and others.
On the basis of end-user, the market has been segmented into
hospitals, clinical laboratories, and others.
Key Players
Some of the prominent players in the global chronic
granulomatous disease market are Pfizer, Inc., InterMune, Inc., Novartis AG,
Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen
Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co.,
Ltd., Maxcyte Inc., and Horizon Pharma Plc.
Access Report @ https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447
At Market Research Future (MRFR), we enable our customers
to unravel the complexity of various industries through our Cooked Research
Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients. Our market research studies by
Components, Application, Logistics and market players for global, regional, and
country level market segments, enable our clients to see more, know more, and
do more, which help to answer all their most important questions.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
Phone:
+1 628 258 0071(US)
+44 2035 002 764(UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
Comments
Post a Comment